Inspire Medical Systems Announces $200M Share Repurchase Program

Inspire Medical Systems announced that its Board of Directors has authorized a share repurchase program of up to $200 million, reflecting confidence in the company's growth prospects and belief that its stock is undervalued. The repurchase program, which may continue until August 7, 2027, is part of a strategy to support the launch of Inspire V, their next-generation neurostimulation system for obstructive sleep apnea, while returning capital to shareholders and investing in future growth. Tim Herbert, Chairman and CEO, highlighted that the company is investing in marketing and footprint expansion for the largest product launch in its history, and emphasized the substantial growth potential as the company remains lightly penetrated in its addressable market. The timing, price, and amount of repurchases will be determined at the company's discretion through various transaction methods, with no obligation to repurchase a specific number of shares. Despite strong financial performance and corporate developments, some analysis indicates mixed investor sentiment due to reduced guidance and valuation concerns. Overall, Inspire Medical Systems views the stock repurchase as an attractive investment opportunity amid continued financial strength and market expansion efforts.